White House pledges $3 billion war chest for COVID antiviralsThe Biden Administration has said it will allocate $3 billion of its pandemic rescue plan to the development Share XWhite House pledges $3 billion war chest for COVID antiviralshttps://pharmaphorum.com/news/white-house-pledges-3-billion-war-chest-for-covid-antivirals/
Merck nabs $1.2 billion order for oral COVID antiviral from USThe US government has placed an order with Merck & Co to buy 1.7 million courses of its Share XMerck nabs $1.2 billion order for oral COVID antiviral from UShttps://pharmaphorum.com/news/merck-grabs-1-2-billion-order-for-oral-covid-antiviral-from-us/
New UK biotech Inspira uncloaks with deal to develop inhaled COVID therapyUK biotech Inspira Pharmaceuticals has emerged from stealth mode with a deal with Vectura to develop an inhaled Share XNew UK biotech Inspira uncloaks with deal to develop inhaled COVID therapyhttps://pharmaphorum.com/news/new-uk-biotech-inspira-uncloaks-with-deal-to-develop-inhaled-covid-therapy/
ViiV’s Rukobia cleared in EU as rescue HIV therapyThe European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment Share XViiV’s Rukobia cleared in EU as rescue HIV therapyhttps://pharmaphorum.com/news/viivs-rukobia-cleared-in-eu-as-rescue-hiv-therapy/
BioSig abandons COVID-19 drug trial on safety concernsUS biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury Share XBioSig abandons COVID-19 drug trial on safety concernshttps://pharmaphorum.com/news/biosig-abandons-covid-19-drug-trial-on-safety-concerns/
Gilead starts trials of inhaled remdesivir for earlier-stage COVID-19The first healthy volunteers have started to receive doses of Gilead’s inhaled formulation of remdesivir, which it hopes Share XGilead starts trials of inhaled remdesivir for earlier-stage COVID-19https://pharmaphorum.com/news/gilead-starts-trials-of-inhaled-remdesivir-for-earlier-stage-covid-19/
ViiV gets FDA nod for Rukobia drug for older HIV patientsThe FDA has approved Rukobia, a first-in-class drug from ViiV Healthcare intended for older people with HIV, who Share XViiV gets FDA nod for Rukobia drug for older HIV patientshttps://pharmaphorum.com/news/viiv-gets-fda-nod-for-rukobia-drug-for-older-hiv-patients/
Atriva takes MEK inhibitor into phase 2 for COVID-19Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, Share XAtriva takes MEK inhibitor into phase 2 for COVID-19https://pharmaphorum.com/news/atriva-takes-mek-inhibitor-into-phase-2-for-covid-19/
Coronavirus news roundup 09/04/2020As the number of coronavirus cases in the world exceeds 1.4 million, the pharma industry is pushing to Share XCoronavirus news roundup 09/04/2020https://pharmaphorum.com/views-and-analysis/coronavirus-news-roundup-09-04-2020/
